High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates.

Bioconjug Chem. 1999 Mar-Apr;10(2):186-91. Unique Identifier : AIDSLINE MED/99177071
Josephson L; Tung CH; Moore A; Weissleder R; Center for Molecular Imaging Research, Massachusetts General; Hospital, Boston, Massachusetts 02129, USA.

Abstract: A biocompatible, dextran coated superparamagnetic iron oxide particle was derivatized with a peptide sequence from the HIV-tat protein to improve intracellular magnetic labeling of different target cells. The conjugate had a mean particle size of 41 nm and contained an average of 6.7 tat peptides. Derivatized particles were internalized into lymphocytes over 100-fold more efficiently than nonmodified particles, resulting in up to 12.7 x 10(6) particles/cell. Internalized particles localized in cytoplasm and nuclear compartments as demonstrated by fluorescence microscopy and immunohistochemistry. Labeled cells were highly magnetic, were detectable by NMR imaging, and could be retained on magnetic separation columns. The described method has potential applications for in vivo tracking of magnetically labeled cells by MR imaging and for recovering intracellularly labeled cells from organs.

Keywords: JOURNAL ARTICLE Amino Acid Sequence Animal Biocompatible Materials Cross-Linking Reagents Ferric Compounds/*PHARMACOKINETICS Fluorescein-5-isothiocyanate Gene Products, tat/CHEMICAL SYNTHESIS/*PHARMACOKINETICS Hela Cells Human Killer Cells, Natural/CYTOLOGY/METABOLISM Lymphocytes/*CYTOLOGY/METABOLISM *Magnetics Mice Microscopy, Fluorescence/METHODS Nuclear Magnetic Resonance Peptide Fragments/CHEMICAL SYNTHESIS/*PHARMACOKINETICS
990730
A9971220

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .